NASDAQ:CAPR
Capricor Therapeutics Stock News
$5.24
-0.0900 (-1.69%)
At Close: May 02, 2024
Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09:00am, Tuesday, 07'th Sep 2021
-Conference Dates: September 13–15, 2021- -Conference Dates: September 13–15, 2021-
Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
08:30am, Thursday, 02'nd Sep 2021
-Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Presentation, One of Only Three Selected by WMS- -Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral P
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2021 Results - Earnings Call Transcript
11:14pm, Thursday, 12'th Aug 2021
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2021 Results - Earnings Call Transcript
Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12
09:00am, Thursday, 05'th Aug 2021
Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET
Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength?
09:01am, Wednesday, 23'rd Jun 2021
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
Capricor Therapeutics to Participate in BIO Digital 2021 Conference
09:15am, Thursday, 10'th Jun 2021
LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the t
-Capricor's Findings Support Expansion Across Multiple Therapeutic Targets-
Capricor Therapeutics, Inc.'s (CAPR) CEO Linda Marbán on Q1 2021 Results - Earnings Call Transcript
10:05pm, Thursday, 13'th May 2021
Capricor Therapeutics, Inc.'s (CAPR) CEO Linda Marbán on Q1 2021 Results - Earnings Call Transcript
Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13
08:30am, Thursday, 06'th May 2021
Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ET Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ET
Capricor Therapeutics Stock Jumps On Engineered Exosomes Development Pact
11:51am, Thursday, 29'th Apr 2021
Capricor Therapeutics (NASDAQ: CAPR) has signed an exclusive, worldwide licensing agreement with Johns Hopkins University (JHU) to include engineered exosomes for vaccines and therapeutics as part
CAPR Stock: From $3.95 To Over $4.20 Pre-Market Explanation
08:32am, Thursday, 29'th Apr 2021
The stock price of Capricor Therapeutics Inc (NASDAQ: CAPR) went from a previous close of $3.95 to over $4.20 pre-market. This is why it happened.
Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q4 2020 Results - Earnings Call Transcript
09:15pm, Thursday, 11'th Mar 2021
Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q4 2020 Results - Earnings Call Transcript
Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
04:01pm, Thursday, 11'th Mar 2021
Exosomes Platform Technology -Pre-IND Meeting with FDA this Quarter to Discuss Multivalent Exosome-mRNA Vaccine--Pipeline Expansion Underway Using Engineered Exosomes-
Capricor Therapeutics - Shockingly Undervalued With Imminent Catalysts In Play
10:27am, Tuesday, 09'th Feb 2021
Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and impacts approximately six per 100,000 individuals in North America and Europe. Current treatments
Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
09:15am, Monday, 01'st Feb 2021
-Technology Licensed from Johns Hopkins University-
